|ISSUE 2 - JAN. 10, 2014|
On Jan. 30, somebody will have to climb to the top of Orlando Health’s 10-story Charles Lewis Pavilion to cover up—or start removing—the backlit letters that, with a halo effect created by LED lights, broadcast the health system’s affiliation with MD Anderson Cancer Center.
The name of the distant, venerable cancer center will vanish from Orlando’s skyline. The distinctive red swoosh that symbolically negates the word “cancer” will be gone also.
|Orlando Health President Mark Roh:
We Opted For a Florida-Centric Strategy
Orlando Health is choosing a partnership over an affiliation, said Mark Roh, president of the Florida cancer center that’s ending its relationship with MD Anderson Cancer Center. Instead, Roh’s hospital is joining the University of Florida to create the UF Health Cancer Center at Orlando Health.
|Ludwig Cancer Research Donates
$540 Million to Six Centers
Ludwig Cancer Research donated a total of $540 million to six of its centers, located at institutions across the country.
|AVEO's Tivozanib Fails In Colorectal Cancer
AVEO Oncology said that data from a planned interim analysis of the phase II BATON (Biomarker Assessment of Tivozanib in ONcology) study in patients with colorectal cancer indicate that the study is unlikely to meet the primary endpoint in the intent-to-treat patient population.
|Task Force Issues Guideline On LDCT Lung Screening
The U.S. Preventive Services Task Force released its final recommendation statement on screening for lung cancer with low-dose computed tomography.
|ACS: Decline in Death Rates Saved
Over 1.3 Million Lives
Declines in death rates over past two decades have added up to a 20 percent drop in the overall risk of dying from cancer, according to the American Cancer Society’s annual statistics report.